For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 10 results
Author Title [ Type(Desc)] Year
Filters: Author is Crystal, R G  [Clear All Filters]
Journal Article
Mack CA, Song WR, Carpenter H, Wickham TJ, Kovesdi I, Harvey BG, Magovern CJ, Isom OW, Rosengart T, Falck-Pedersen E et al..  1997.  Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.. Hum Gene Ther. 8(1):99-109.
Gall JG, Crystal RG, Falck-Pedersen E.  1998.  Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype.. J Virol. 72(12):10260-4.
Abrahamsen K, Kong HL, Mastrangeli A, Brough D, Lizonova A, Crystal RG, Falck-Pedersen E.  1997.  Construction of an adenovirus type 7a E1A- vector.. J Virol. 71(11):8946-51.
Wolff G, Mastrangeli A, Heinflink M, Falck-Pedersen E, Gershengorn MC, Crystal RG.  1996.  Ectopic expression of thyrotropin releasing hormone (TRH) receptors in liver modulates organ function to regulate blood glucose by TRH.. Nat Genet. 12(3):274-9.
Miyazawa N, Leopold PL, Hackett NR, Ferris B, Worgall S, Falck-Pedersen E, Crystal RG.  1999.  Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors.. J Virol. 73(7):6056-65.
Peng Y, Trevejo J, Zhou J, Marino MW, Crystal RG, Falck-Pedersen E, Elkon KB.  1999.  Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung.. J Virol. 73(6):5098-109.
Worgall S, Wolff G, Falck-Pedersen E, Crystal RG.  1997.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.. Hum Gene Ther. 8(1):37-44.
Kaner RJ, Worgall S, Leopold PL, Stolze E, Milano E, Hidaka C, Ramalingam R, Hackett NR, Singh R, Bergelson J et al..  1999.  Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor.. Am J Respir Cell Mol Biol. 20(3):361-70.
Mastrangeli A, Harvey BG, Yao J, Wolff G, Kovesdi I, Crystal RG, Falck-Pedersen E.  1996.  "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype.. Hum Gene Ther. 7(1):79-87.
Elkon KB, Liu CC, Gall JG, Trevejo J, Marino MW, Abrahamsen KA, Song X, Zhou JL, Old LJ, Crystal RG et al..  1997.  Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors.. Proc Natl Acad Sci U S A. 94(18):9814-9.